Production (Stage)
Tango Therapeutics, Inc.
TNGX
$1.84
-$0.025-1.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -132.26M | -130.30M | -123.40M | -116.49M | -111.65M |
| Total Depreciation and Amortization | 2.50M | 2.50M | 2.50M | 2.49M | 2.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.36M | 28.05M | 23.93M | 23.53M | 21.37M |
| Change in Net Operating Assets | -34.93M | -31.75M | -25.35M | -29.59M | -33.11M |
| Cash from Operations | -135.34M | -131.50M | -122.32M | -120.07M | -120.93M |
| Capital Expenditure | -610.00K | -754.00K | -856.00K | -757.00K | -1.10M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 128.54M | 86.88M | 68.77M | -20.56M | -227.00K |
| Cash from Investing | 127.93M | 86.13M | 67.92M | -21.32M | -1.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.68M | 47.66M | 48.40M | 126.28M | 125.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -241.00K | -241.00K | -241.00K |
| Cash from Financing | 4.68M | 47.66M | 48.16M | 126.04M | 125.32M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.73M | 2.29M | -6.24M | -15.34M | 3.06M |